^
    Back
    Association details:
    Biomarker:CRBN expression
    Cancer:Multiple Myeloma
    Drug:lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Lenalidomide Maintenance Therapy for Multiple Myeloma

    Excerpt:
    ...Number of Participants With Serious and Non-serious Adverse Events`Duration of Response`Progression Free Survival (PFS)`Natural Killer (NK) Cell Function and Activity`Changes in B Cell Subsets, Myeloid Derived Suppressor Cells and T Regulatory Cells by Phenotypic Analysis During the Course of Therapy`Expression of Cereblon (CRBN) and How it Relates to Natural Killer (NK) Cell Number and Activity...
    Trial ID:
    NCT01675141
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Clin Med
    Title:

    The CRBN, CUL4A and DDB1 Expression Predicts the Response to Immunomodulatory Drugs and Survival of Multiple Myeloma Patients

    Published date:
    06/18/2021
    Excerpt:
    ...MM patients treated with thalidomide or lenalidomide-based regimens. We found that the expression of CRBN and CUL4A was associated with the superior IMiD-based treatment response (p = 0.007 and p = 0.007, respectively).
    DOI:
    10.3390/jcm10122683